ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Role of immune dysregulation in aristolochic acid-induced multisystem toxicities: an insight from systems toxicology.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to aristolochic acids [AAs, including aristolochic acid Ⅰ (AAⅠ), aristolochic acid Ⅱ (AAⅡ), and aristololactam Ⅰ (ALⅠ)] has cast a shadow over public health due to the global therapeutic usage of the Aristolochiaceae herbs comprising AAs. Evidence is mounting that AAs exposure is definitely responsible for multisystem toxicities. The toxicological landscape of AAs, implicating toxic effects, toxicity targets, and toxicity signaling pathways, has yet to be thoroughly disentangled. We used the structure information of AAⅠ, AAⅡ, and ALⅠ to outline AAs multisystem toxicities. AAs targets were integrated to construct AAs-targets network and analyze their tissue and disease distribution. The intersections of AAs targets and the system-level toxicity targets were used for protein-protein interaction (PPI) analysis, core target identification, and functional annotation and enrichment analysis. We used two-sample Mendelian randomization (2SMR) to assess causal associations between the core targets and toxic effects. Molecular docking and molecular dynamics simulation (MDS) were applied to verifying the binding affinity of AAs with the core targets. AAs multisystem toxicities implicated renal, hepatic, neural, respiratory, reproductive, and hematic disorders. The network analysis with 2SMR evidence showed that TNF as the common target lay at the nexus of AAs multisystem toxicities. The signaling pathways underlying AAs toxic effects were functionally categorized as immune dysregulation, cell injury/apoptosis, abnormal blood supply, oxidative stress, and metabolic dysfunction. Immune dysregulation involved the shared signaling pathway "AGE-RAGE signaling pathway" that could trigger TNF overexpression and boost TNF signaling cascade. The profiling of AAs immunotoxic properties highlighted the essentiality of TNF and TNF signaling pathway in AAs-related immune dysregulation. The high-affinity binding of AAs to the core targets was illustrated via molecular docking and MDS. These findings demonstrate that immune dysregulation is instrumental in AAs multisystem toxicities. Disturbing AGE-RAGE axis and TNF signaling primes the hub mechanism of AAs toxic effects.
Indexed as
Identifiers
42631857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.